Pharmalot

Pharmalot

Pharmalittle: Need cheap insulin? Try Craigslist; Trump warned about monopolies on coronavirus treatments

By Ed Silverman

Pharmalot

Lawmakers to Trump: Don’t give ‘monopolies’ to companies that develop coronavirus treatments with taxpayer funds

By Ed Silverman

Pharmalot

How many? The coronavirus is prompting a burst of clinical trials in search of a treatment

By Ed Silverman

Pharmalot

Pharma execs criticize a drug maker over pricing and claim orphan drug law is being misused

By Ed Silverman

Pharmalot

Pharmalittle: Prices for active ingredients rise in India due to coronavirus; Grassley presses his drug pricing bill

By Ed Silverman

Pharmalot

Consumer groups and unions try again to block the AbbVie and Allergan merger

By Ed Silverman

Pharmalot

Pharmalittle: Coronavirus clinical trials are going slower than hoped; opioid lawsuit payouts may be less than expected

By Ed Silverman

Pharmalot

A city in Georgia is the latest to sue Mallinckrodt over its pricey Acthar Gel medicine

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Generic shortages loom as coronavirus worsens; Connecticut lawmakers look to cap insulin costs

By Ed Silverman

Pharmalot

Americans with employer coverage saw growth in drug spending outpace other medical costs

By Ed Silverman

Pharmalot

As opioid crisis intensified, many family doctors found promotional pitches were very good

By Ed Silverman

Pharmalot

Pharmalittle: India struggles with coronavirus; CVS and Sanofi shake up management

By Ed Silverman

Pharmalot

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

By Ed Silverman

Pharmalot

Pharmalittle: Big pharma isn’t stepping up to make a coronavirus vaccine; Chinese drug maker threatens Gilead patent

By Ed Silverman

Pharmalot

After a new version of a decades-old drug gets orphan status, the price suddenly skyrockets

By Ed Silverman

Pharmalot

WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’

By Ed Silverman

Pharmalot

Pharmalittle: Trump considers executive action to cut drug prices; feds ‘not done’ with generic price-fixing probe

By Ed Silverman

Pharmalot

Pharmalittle: Two more Alzheimer’s drugs fail in studies; how Democratic candidates differ on lowering drug costs

By Ed Silverman

Pharmalot

California scolds McKesson for supplying excessive controlled substances to a children’s pharmacy

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Novartis lottery for gene therapy begins amid tough questions; coronavirus vaccine may take a year

By Ed Silverman

Pharmalot

U.S. officials lash out at the Dutch government for moves that ‘undermine’ pharma patent rights

By Ed Silverman

Pharmalot

Pharmalittle: Buttigieg wants pharma to ‘thrive’; U.S. patent panel boosts Biogen, disappoints Gilead

By Ed Silverman

Pharmalot

Years later, raw clinical trial data tells us the extent of Avandia’s heart risks

By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalittle: Canada may change new rules for drug prices; Trump frustrated over drug pricing

Gilead loses another challenge to a pair of U.S. patents for an HIV prevention pill

Rising out-of-pocket costs for dementia and neuropathy drugs lower patient adherence

Pharmalittle: Need cheap insulin? Try Craigslist; Trump warned about monopolies on coronavirus treatments

Lawmakers to Trump: Don’t give ‘monopolies’ to companies that develop coronavirus treatments with taxpayer funds

How many? The coronavirus is prompting a burst of clinical trials in search of a treatment

Pharma execs criticize a drug maker over pricing and claim orphan drug law is being misused

Pharmalittle: Prices for active ingredients rise in India due to coronavirus; Grassley presses his drug pricing bill

Consumer groups and unions try again to block the AbbVie and Allergan merger

Pharmalittle: Coronavirus clinical trials are going slower than hoped; opioid lawsuit payouts may be less than expected

A city in Georgia is the latest to sue Mallinckrodt over its pricey Acthar Gel medicine

Up and down the ladder: The latest comings and goings

Pharmalittle: Generic shortages loom as coronavirus worsens; Connecticut lawmakers look to cap insulin costs

Americans with employer coverage saw growth in drug spending outpace other medical costs

As opioid crisis intensified, many family doctors found promotional pitches were very good

Pharmalittle: India struggles with coronavirus; CVS and Sanofi shake up management

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

Pharmalittle: Big pharma isn’t stepping up to make a coronavirus vaccine; Chinese drug maker threatens Gilead patent

After a new version of a decades-old drug gets orphan status, the price suddenly skyrockets

WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’

Pharmalittle: Trump considers executive action to cut drug prices; feds ‘not done’ with generic price-fixing probe

Pharmalittle: Two more Alzheimer’s drugs fail in studies; how Democratic candidates differ on lowering drug costs

California scolds McKesson for supplying excessive controlled substances to a children’s pharmacy

Up and down the ladder: The latest comings and goings

Pharmalittle: Novartis lottery for gene therapy begins amid tough questions; coronavirus vaccine may take a year

U.S. officials lash out at the Dutch government for moves that ‘undermine’ pharma patent rights

Pharmalittle: Buttigieg wants pharma to ‘thrive’; U.S. patent panel boosts Biogen, disappoints Gilead

Years later, raw clinical trial data tells us the extent of Avandia’s heart risks